Literature DB >> 3060361

An objective evaluation of once-daily sustained-release verapamil (480 mg) in chronic stable angina.

E A Rodrigues1, P DasGupta, A D Hains, E B Raftery.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3060361     DOI： 10.1007/bf01046717

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  3 in total

1.  Sustained release verapamil, a once daily preparation: objective evaluation using exercise testing, ambulatory monitoring and blood levels in patients with stable angina.

Authors:  R S Kohli; E A Rodrigues; L O Hughes; A Lahiri; E B Raftery
Journal:  J Am Coll Cardiol       Date:  1987-03       Impact factor: 24.094

2.  Long-term antianginal action of verapamil assessed with quantitated serial treadmill stress testing.

Authors:  B Subramanian; M Bowles; A Lahiri; A B Davies; E B Raftery
Journal:  Am J Cardiol       Date:  1981-09       Impact factor: 2.778

3.  Randomized double-blind comparison of verapamil and nifedipine in chronic stable angina.

Authors:  V B Subramanian; M J Bowles; N S Khurmi; A B Davies; E B Raftery
Journal:  Am J Cardiol       Date:  1982-10       Impact factor: 2.778
  3 in total
  1 in total

1.  Sustained-release and instant-release verapamil in treatment of angina pectoris.

Authors:  C M Jespersen; N A Klitgaard; H Nielsen; J F Hansen
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.